# Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

> **NCT07247292** · — · SUSPENDED · sponsor: **AstraZeneca** · enrollment: 100 (estimated)

## Conditions studied

- Rare Diseases
- Neuromyelitis Optica Spectrum Disorder (NMOSD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07247292
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-12-23
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** As a part of portfolio and planning reassessment for the current period, a decision has been made to prioritize, optimize and reallocate resources. As a result, enrollment and other study activities have been temporarily paused.
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247292, "Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07247292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*